Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors

References

• Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WT, de Vries EG, Sleijfer DT, et al. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev 2000; 26: 429–47
   PubMed Web of Science ®Google Scholar
• Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995–1000
   PubMed Web of Science ®Google Scholar
• Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, et al. Apoptosis in the failing human heart. N Engl J Med 1997; 336: 1131–41
   PubMed Web of Science ®Google Scholar
• Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201–6
   PubMed Web of Science ®Google Scholar
• Nishigaki K, Minatoguchi S, Seishima M, Asano K, Noda T, Yasuda N, et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 1997; 29: 1214–20
   PubMed Web of Science ®Google Scholar
• Yndestad A, Kristian DJ, Geir EH, Holm T, Haug T, Simonsen S, et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res 2002; 54: 175–82
   PubMed Web of Science ®Google Scholar
• Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: Effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103: 1746–51
   PubMed Web of Science ®Google Scholar
• Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004; 147: 931–8
   PubMed Web of Science ®Google Scholar
• Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999; 33: 1424–6
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–82
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92
   PubMed Web of Science ®Google Scholar
• Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002; 99: 8880–5
   PubMed Web of Science ®Google Scholar
• Harris L, Luftner D, Jager W, Robertson JF. c-erbB-2 in serum of patients with breast cancer. Int J Biol Markers 1999; 14: 8–15
   PubMedGoogle Scholar
• McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9–13
   PubMed Web of Science ®Google Scholar
• Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996; 77: 828–31
   PubMed Web of Science ®Google Scholar
• Meinardi MT, van Veldhuisen DJ, Gietema JA, Dolsma WV, Boomsma F, Van den Berg MP, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001; 19: 2746–53
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349: 7–16
   PubMed Web of Science ®Google Scholar
• Gelevert T, Messerschmidt J, Meinardi MT, Alt F, Gietema JA, Franke JP, et al. Adsorptive voltametry to determine platinum levels in plasma from testicular cancer patients treated with cisplatin. Ther Drug Monit 2001; 23: 169–73
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988; 319: 1239–45
   PubMed Web of Science ®Google Scholar
• Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998; 136: 362–3
   PubMed Web of Science ®Google Scholar
• Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599–610
   PubMed Web of Science ®Google Scholar
• Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40: 701–6
   PubMed Web of Science ®Google Scholar
• Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 355: 1075–6
   PubMed Web of Science ®Google Scholar
• de Vos FY, Nuver J, Willemse PH, van der Zee AG, Masserschmidt J, Burgerhof JG, et al. Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage. Eur J Cancer 2004; 40: 696–700
   PubMed Web of Science ®Google Scholar
• Nagarkatti N, Davis BA. Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand. Cancer Chemother Pharmacol 2003; 51: 284–90
   PubMed Web of Science ®Google Scholar
• Girinsky TA, Pallardy M, Comoy E, Benassi T, Roger R, Ganem G, et al. Peripheral blood corticotropin-releasing factor, adrenocorticotropic hormone and cytokine (interleukin beta, interleukin 6, tumor necrosis factor alpha) levels after high- and low-dose total-body irradiation in humans. Radiat Res 1994; 139: 360–3
   PubMedGoogle Scholar
• Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000; 6: 2356–62
   PubMed Web of Science ®Google Scholar
• Lichtenstein A, Berenson J, Gera JF, Waldburger K, Martinez Maza O, Berek JS, et al. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: Correlation with expression of HER2/neu oncogenes. Cancer Res 1990; 50: 7364–70
   PubMed Web of Science ®Google Scholar
• Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002; 64: 604–11
   PubMed Web of Science ®Google Scholar